Helus Pharma Inc.
- Ticker
- HELP
- Exchange
- NEO
- Country
- Canada
Price History
Business
Company profile
AER Insights
Biotechnology & HealthcareHelus Pharma’s Depression Trial Succeeds as Safety and Funding Questions Move Forward
Helus Pharma’s HLP003 met the primary endpoint in its first pivotal depression trial, producing a 7.6-point advantage over placebo on a symptom scale at six weeks. Patients remained on their existing antidepressants, and the benefit persisted at the study’s 12-week assessment. The results strengthen the case for an intermittent add-on treatment, although the nature of three treatment-related serious adverse events remains undisclosed. Quarterly filings show $171.1 million in cash at September 30 and continued clinical spending ahead of a second pivotal readout expected in late 2027.
Biotechnology & HealthcareHelus Pharma Redesigns Its Anxiety Study as Pivotal Depression Data Approach
Helus is moving HLP004 into a larger, placebo-controlled monotherapy study while its lead depression drug approaches a Phase 3 readout. The revised anxiety program could establish a clearer efficacy signal, but near-term shareholder value depends more heavily on HLP003 and the cost of completing its development.
Financials
Fundamental data
Market information is supplied by TradingView and may be delayed or unavailable for certain exchanges or instruments. It does not constitute investment advice.
Alliance Equity Research Coverage
No current AER coverage
Related AER Insights are available above. This company does not currently have published AER company coverage.
Request Coverage